FEATURES >> Top 5 Biotech VC Deals of 2010
Top Story
Sanofi-Aventis readies $18.7B bid for Genzyme
Genzyme (GENZ) is in play. After days of fevered speculation over what Genzyme would be worth to a company like Sanofi-Aventis, the big pharma outfit appears to have set its sights on the low side of the spectrum. According to a flurry of news reports, Sanofi CEO Chris Viehbacher and the board think that $70 a share--that's $18.7 billion total--would be a fair price to pay. But any bidding could start under that level. Read more...
Latest News
Also Noted
@FierceBiotech: Top 5 Biotech VC Deals of 2010. Article | Follow @FierceBiotech
@JohnCFierce: New idea: Offer EMA-approved drugs in U.S., fostering regulatory competition. I'll expect this three days after hell freezes. Story | Follow @JohnCFierce
> Seattle-based Omeros has struck a deal to sell up to $40 million in shares to a single investor--Azimuth Opportunity. "This financing vehicle provides flexibility and potentially strengthens our position as we pursue strategic opportunities," says CEO Gregory Demopulos. Release
> The FDA has approved Shionogi's new drug to treat severe drooling in patients with neurological disorders. Report
Read more >>Press Releases
- GSK EXERCISES OPTION ON ANACOR'S NOVEL ANTIBIOTIC FOR THE TREATMENT OF GRAM-NEGATIVE INFECTIONS
- Formatech to Donate Services to Formulate and Fill Femta Pharmaceuticals’ FM101 Monoclonal Antibody under Its “Fillanthrop
- Inhibitex to Host Conference Call to Report Second Quarter Financial Results on August 10, 2010
- Amgen’s Second Quarter 2010 Adjusted Earnings Per Share Increased 7 Percent to $1.38
- Response Genetics, Inc. to Announce Second Quarter 2010 Financial Results
- The Multiple Myeloma Research Foundation (MMRF) Names Walter Capone Chief Operating Officer
More News
Five high-value biotech stocks
Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value plays in the months ahead. In the mood for some market risk analysis? Then check out these five companies. Report
Special Report
Top 5 Biotech VC Deals of 2010
